Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody
Background. Beta-cell antibody tests are used for the differential diagnosis of diabetes mellitus. They permit to discriminate between the type 1 diabetes (T1D) and non-autoimmune diabetes types. To choose an appropriate test for ruling in or ruling out the T1D a physician needs to know how conclusi...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/622cca5c774b4d348a210b0825e4ea01 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:622cca5c774b4d348a210b0825e4ea01 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:622cca5c774b4d348a210b0825e4ea012021-11-14T09:00:21ZDifferential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody2072-03512072-037810.14341/DM9364https://doaj.org/article/622cca5c774b4d348a210b0825e4ea012018-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9364https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Background. Beta-cell antibody tests are used for the differential diagnosis of diabetes mellitus. They permit to discriminate between the type 1 diabetes (T1D) and non-autoimmune diabetes types. To choose an appropriate test for ruling in or ruling out the T1D a physician needs to know how conclusive test results are. The most powerful estimate of test conclusiveness is its likelihood ratio (LHR). The higher LHR of a positive result (LHR+), the more posttest probability of T1D; the lower LHR of a negative result (LHR−), the less posttest probability of T1D. Aims. To compare conclusiveness of single and combined tests for antibodies to islet cells (ICA), glutamate decarboxylase (GADA), and tyrosine phosphatase IA-2 (IA-2A), and to evaluate posttest probabilities of T1D at various pretest probabilities. Methods. All antibodies were tested in parallel in 169 children and adolescents with a new-onset T1D, and in 169 persons without this disease. ICA, GADA, and IA-2A were determined by indirect immunofluorescence, radioimmune assay, and ELISA, respectively. LHR+ and LHR− were calculated with the MedCalc Statistical Software. Posttest T1D probabilities were calculated from Bayes theorem-based equation. Results. Among single tests, an ICA test had the greatest LHR+ and the smallest LHR−, and consequently was the most reliable either for ruling in or ruling out the T1D. Among test combinations, an ICA&GADA combination had the greatest LHR+ and was the most suitable for T1D confirmation. The triple combination ICA&GADA&IA-2A had the smallest LHR− and was the most suitable for T1D exclusion. Conclusions. In the differential diagnosis of diabetes, the most appropriate test for ruling in the T1D is the double combination ICA&GADA. With both antibodies positive, this combination provides the highest posttest T1D probabilities at any pretest probability. The most appropriate test for ruling out the T1D is the triple combination ICA&GADA&IA-2A. With all three antibodies negative, this combination provides the lowest posttest T1D probabilities.Alexei V. TimofeevIgor E. KoltunovElena E. PetriaikinaIrina G. RybkinaLubov N. SamsonovaAnatoly N. TiulpakovNatalia A. ZubkovaIrina G. KolominaEvgenia A. EvsjukovaSergey S. BukinAlexey C. KhrushchevEndocrinology Research Centrearticlediabetes mellitusdifferential diagnosisislet cell antibodyica512 antibodyglutamate decarboxylase antibodyoperational characteristicslikelihood ratioNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 2, Pp 74-83 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
diabetes mellitus differential diagnosis islet cell antibody ica512 antibody glutamate decarboxylase antibody operational characteristics likelihood ratio Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
diabetes mellitus differential diagnosis islet cell antibody ica512 antibody glutamate decarboxylase antibody operational characteristics likelihood ratio Nutritional diseases. Deficiency diseases RC620-627 Alexei V. Timofeev Igor E. Koltunov Elena E. Petriaikina Irina G. Rybkina Lubov N. Samsonova Anatoly N. Tiulpakov Natalia A. Zubkova Irina G. Kolomina Evgenia A. Evsjukova Sergey S. Bukin Alexey C. Khrushchev Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| description |
Background. Beta-cell antibody tests are used for the differential diagnosis of diabetes mellitus. They permit to discriminate between the type 1 diabetes (T1D) and non-autoimmune diabetes types. To choose an appropriate test for ruling in or ruling out the T1D a physician needs to know how conclusive test results are. The most powerful estimate of test conclusiveness is its likelihood ratio (LHR). The higher LHR of a positive result (LHR+), the more posttest probability of T1D; the lower LHR of a negative result (LHR−), the less posttest probability of T1D.
Aims. To compare conclusiveness of single and combined tests for antibodies to islet cells (ICA), glutamate decarboxylase (GADA), and tyrosine phosphatase IA-2 (IA-2A), and to evaluate posttest probabilities of T1D at various pretest probabilities.
Methods. All antibodies were tested in parallel in 169 children and adolescents with a new-onset T1D, and in 169 persons without this disease. ICA, GADA, and IA-2A were determined by indirect immunofluorescence, radioimmune assay, and ELISA, respectively. LHR+ and LHR− were calculated with the MedCalc Statistical Software. Posttest T1D probabilities were calculated from Bayes theorem-based equation.
Results. Among single tests, an ICA test had the greatest LHR+ and the smallest LHR−, and consequently was the most reliable either for ruling in or ruling out the T1D. Among test combinations, an ICA&GADA combination had the greatest LHR+ and was the most suitable for T1D confirmation. The triple combination ICA&GADA&IA-2A had the smallest LHR− and was the most suitable for T1D exclusion.
Conclusions. In the differential diagnosis of diabetes, the most appropriate test for ruling in the T1D is the double combination ICA&GADA. With both antibodies positive, this combination provides the highest posttest T1D probabilities at any pretest probability. The most appropriate test for ruling out the T1D is the triple combination ICA&GADA&IA-2A. With all three antibodies negative, this combination provides the lowest posttest T1D probabilities. |
| format |
article |
| author |
Alexei V. Timofeev Igor E. Koltunov Elena E. Petriaikina Irina G. Rybkina Lubov N. Samsonova Anatoly N. Tiulpakov Natalia A. Zubkova Irina G. Kolomina Evgenia A. Evsjukova Sergey S. Bukin Alexey C. Khrushchev |
| author_facet |
Alexei V. Timofeev Igor E. Koltunov Elena E. Petriaikina Irina G. Rybkina Lubov N. Samsonova Anatoly N. Tiulpakov Natalia A. Zubkova Irina G. Kolomina Evgenia A. Evsjukova Sergey S. Bukin Alexey C. Khrushchev |
| author_sort |
Alexei V. Timofeev |
| title |
Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| title_short |
Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| title_full |
Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| title_fullStr |
Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| title_full_unstemmed |
Differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| title_sort |
differential diagnostic utilities of combined testing for islet cell antibody, glutamic acid decarboxylase antibody, and tyrosine phosphatase antibody |
| publisher |
Endocrinology Research Centre |
| publishDate |
2018 |
| url |
https://doaj.org/article/622cca5c774b4d348a210b0825e4ea01 |
| work_keys_str_mv |
AT alexeivtimofeev differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT igorekoltunov differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT elenaepetriaikina differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT irinagrybkina differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT lubovnsamsonova differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT anatolyntiulpakov differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT nataliaazubkova differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT irinagkolomina differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT evgeniaaevsjukova differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT sergeysbukin differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody AT alexeyckhrushchev differentialdiagnosticutilitiesofcombinedtestingforisletcellantibodyglutamicaciddecarboxylaseantibodyandtyrosinephosphataseantibody |
| _version_ |
1718429531689189376 |